525 related articles for article (PubMed ID: 15451783)
1. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.
Koenig W; Twardella D; Brenner H; Rothenbacher D
Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1586-93. PubMed ID: 16627803
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Chambless LE; Myerson M; Wu KK; Sharrett AR; Boerwinkle E
Arch Intern Med; 2005 Nov; 165(21):2479-84. PubMed ID: 16314544
[TBL] [Abstract][Full Text] [Related]
5. Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index.
Santos S; Rooke TW; Bailey KR; McConnell JP; Kullo IJ
Vasc Med; 2004 May; 9(3):171-6. PubMed ID: 15675180
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.
Oei HH; van der Meer IM; Hofman A; Koudstaal PJ; Stijnen T; Breteler MM; Witteman JC
Circulation; 2005 Feb; 111(5):570-5. PubMed ID: 15699277
[TBL] [Abstract][Full Text] [Related]
7. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
[TBL] [Abstract][Full Text] [Related]
8. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients.
Corsetti JP; Rainwater DL; Moss AJ; Zareba W; Sparks CE
Clin Chem; 2006 Jul; 52(7):1331-8. PubMed ID: 16709622
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.
May HT; Horne BD; Anderson JL; Wolfert RL; Muhlestein JB; Renlund DG; Clarke JL; Kolek MJ; Bair TL; Pearson RR; Sudhir K; Carlquist JF
Am Heart J; 2006 Nov; 152(5):997-1003. PubMed ID: 17070179
[TBL] [Abstract][Full Text] [Related]
10. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up.
Brilakis ES; McConnell JP; Lennon RJ; Elesber AA; Meyer JG; Berger PB
Eur Heart J; 2005 Jan; 26(2):137-44. PubMed ID: 15618069
[TBL] [Abstract][Full Text] [Related]
11. The effect of statin therapy on lipoprotein associated phospholipase A2 levels.
Albert MA; Glynn RJ; Wolfert RL; Ridker PM
Atherosclerosis; 2005 Sep; 182(1):193-8. PubMed ID: 15982658
[TBL] [Abstract][Full Text] [Related]
12. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
Sudhir K
J Clin Endocrinol Metab; 2005 May; 90(5):3100-5. PubMed ID: 15713711
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
Packard CJ; O'Reilly DS; Caslake MJ; McMahon AD; Ford I; Cooney J; Macphee CH; Suckling KE; Krishna M; Wilkinson FE; Rumley A; Lowe GD
N Engl J Med; 2000 Oct; 343(16):1148-55. PubMed ID: 11036120
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.
Jabor B; Choi H; Ruel I; Hafiane A; Mourad W; Genest J
Can J Cardiol; 2013 Dec; 29(12):1679-86. PubMed ID: 24267807
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam study.
van Vark LC; Kardys I; Bleumink GS; Knetsch AM; Deckers JW; Hofman A; Stricker BH; Witteman JC
Eur Heart J; 2006 Oct; 27(19):2346-52. PubMed ID: 16952920
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community.
Gerber Y; McConnell JP; Jaffe AS; Weston SA; Killian JM; Roger VL
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2517-22. PubMed ID: 16902161
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein-associated phospholipase A2 is associated with risk of dementia.
van Oijen M; van der Meer IM; Hofman A; Witteman JC; Koudstaal PJ; Breteler MM
Ann Neurol; 2006 Jan; 59(1):139-44. PubMed ID: 16278861
[TBL] [Abstract][Full Text] [Related]
19. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
Xu RX; Zhang Y; Li XL; Li S; Guo YL; Dong Q; Liu G; Li JJ
Clin Chim Acta; 2015 Jun; 446():195-200. PubMed ID: 25934512
[TBL] [Abstract][Full Text] [Related]
20. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
